{"hands_on_practices": [{"introduction": "Differentiating between chronic and latent infections is a cornerstone of clinical microbiology, yet it demands a nuanced interpretation of complex longitudinal data. This practice challenges you to apply formal definitions to a realistic, albeit hypothetical, case study of a betaherpesvirus infection. By analyzing virologic, molecular, and clinical markers over time, you will develop the critical skill of classifying infection states from first principles [@problem_id:2519729].", "problem": "A hypothetical betaherpesvirus infects an immunocompetent adult. Longitudinal sampling captures virologic, molecular, and clinical data. Analytical sensitivity is specified as follows: the quantitative Polymerase Chain Reaction (qPCR) limit of detection (LOD) for plasma virion deoxyribonucleic acid (DNA) is $50$ copies/mL, the reverse-transcription quantitative Polymerase Chain Reaction (RT-qPCR) LOD for immediate-early (IE) messenger ribonucleic acid (mRNA) is $10$ transcripts per $10^{6}$ peripheral blood mononuclear cells (PBMCs), and the LOD for cell-associated viral DNA is $1$ copy per $10^{6}$ PBMCs. Symptom scores are clinician-assessed on a $0$ to $10$ scale, and C-reactive protein (CRP) is tracked as a systemic inflammatory marker. The infection evolves through four empirically defined phases:\n\n- Phase I (weeks $0$ to $6$): Plasma virion DNA peaks at $10^{7}$ copies/mL at week $2$, then declines to $8\\times 10^{3}$ copies/mL by week $6$. IE mRNA is $>10^{4}$ transcripts per $10^{6}$ PBMCs at weeks $1$ to $3$, then $1.2\\times 10^{3}$ by week $6$. Symptom scores $7$ to $9$ initially, declining to $4$ by week $6$. CRP peaks at $60$ mg/L at week $2$.\n- Phase II (weeks $7$ to $28$): Plasma virion DNA fluctuates between $200$ and $600$ copies/mL; IE mRNA between $100$ and $300$ transcripts per $10^{6}$ PBMCs; cell-associated viral DNA $50$ to $90$ copies per $10^{6}$ PBMCs. Symptom scores stabilize between $1$ and $2$. CRP $6$ to $10$ mg/L.\n- Phase III (weeks $29$ to $52$): Plasma virion DNA is consistently $<50$ copies/mL (undetectable by qPCR); IE mRNA is $<10$ transcripts per $10^{6}$ PBMCs (undetectable by RT-qPCR); cell-associated viral DNA persists at $5$ to $20$ copies per $10^{6}$ PBMCs. Symptom score $0$. CRP $2$ to $3$ mg/L (baseline range for this individual).\n- At week $52$, the patient receives prednisone $40$ mg/day for $14$ days for an unrelated autoimmune flare.\n- Phase IV (weeks $53$ to $60$): Plasma virion DNA rebounds to $1.5\\times 10^{4}$ copies/mL at week $54$, then declines to a plateau between $150$ and $300$ copies/mL through week $60$. IE mRNA rises to $5\\times 10^{3}$ transcripts per $10^{6}$ PBMCs at week $54$, tapering to $200$ to $300$ by week $60$. Cell-associated viral DNA increases to $120$ copies per $10^{6}$ PBMCs at week $54$, then $70$ to $90$ by week $60$. Symptom scores increase to $5$ at week $54$ and then remain between $1$ and $2$. CRP rises to $18$ mg/L at week $54$ and returns to $8$ to $10$ mg/L by week $60$.\n\nUsing only first principles from molecular microbiology and infection natural history, infer the subtype of infection state in Phase II, Phase III, and Phase IV, respectively. Choose the single best option that correctly classifies these three phases and is justified by the data shown.\n\nA. Phase II = chronic; Phase III = latent; Phase IV = chronic, because Phase II and IV demonstrate sustained detection of virions and immediate-early transcripts above assay LOD alongside ongoing, albeit mild, clinical and inflammatory activity, whereas Phase III shows genome persistence without detectable productive replication or symptoms.\n\nB. Phase II = persistent; Phase III = latent; Phase IV = persistent, because any infection lasting beyond the acute phase (after week $6$) is persistent regardless of replication markers, and latency is identified solely by absence of symptoms.\n\nC. Phase II = latent; Phase III = chronic; Phase IV = chronic, because low symptom scores define latency, and recurrence of symptoms defines chronicity even if virions are undetectable.\n\nD. Phase II = chronic; Phase III = persistent; Phase IV = latent, because detection of any viral genome implies persistence, and following immunosuppression, the virus reenters latency after a transient spike in viremia that does not alter its latent state.", "solution": "The problem statement must first be rigorously validated.\n\n**Step 1: Extract Givens**\n\n-   **Pathogen**: A hypothetical betaherpesvirus.\n-   **Host**: Immunocompetent adult.\n-   **Assay LODs (Limits of Detection)**:\n    -   Plasma virion DNA (qPCR): $50$ copies/mL.\n    -   Immediate-early (IE) mRNA (RT-qPCR): $10$ transcripts per $10^{6}$ peripheral blood mononuclear cells (PBMCs).\n    -   Cell-associated viral DNA: $1$ copy per $10^{6}$ PBMCs.\n-   **Clinical/Inflammatory Markers**:\n    -   Symptom score: $0$ to $10$ scale.\n    -   C-reactive protein (CRP): mg/L.\n\n-   **Phase I (Acute, weeks $0$ to $6$)**:\n    -   Plasma virion DNA: Peaks at $10^{7}$ copies/mL (week $2$), declines to $8 \\times 10^{3}$ copies/mL (week $6$).\n    -   IE mRNA: $>10^{4}$ transcripts per $10^{6}$ PBMCs (weeks $1$ to $3$), then $1.2 \\times 10^{3}$ (week $6$).\n    -   Symptoms: $7$ to $9$, declining to $4$.\n    -   CRP: Peaks at $60$ mg/L (week $2$).\n\n-   **Phase II (weeks $7$ to $28$)**:\n    -   Plasma virion DNA: $200$ to $600$ copies/mL.\n    -   IE mRNA: $100$ to $300$ transcripts per $10^{6}$ PBMCs.\n    -   Cell-associated viral DNA: $50$ to $90$ copies per $10^{6}$ PBMCs.\n    -   Symptoms: $1$ to $2$.\n    -   CRP: $6$ to $10$ mg/L.\n\n-   **Phase III (weeks $29$ to $52$)**:\n    -   Plasma virion DNA: $<50$ copies/mL (undetectable).\n    -   IE mRNA: $<10$ transcripts per $10^{6}$ PBMCs (undetectable).\n    -   Cell-associated viral DNA: $5$ to $20$ copies per $10^{6}$ PBMCs.\n    -   Symptoms: $0$.\n    -   CRP: $2$ to $3$ mg/L (baseline).\n\n-   **Immunosuppressive Event**: At week $52$, patient receives prednisone $40$ mg/day for $14$ days.\n\n-   **Phase IV (weeks $53$ to $60$)**:\n    -   Plasma virion DNA: Rebounds to $1.5 \\times 10^{4}$ copies/mL (week $54$), then plateaus at $150$ to $300$ copies/mL.\n    -   IE mRNA: Rises to $5 \\times 10^{3}$ transcripts per $10^{6}$ PBMCs (week $54$), tapers to $200$ to $300$.\n    -   Cell-associated viral DNA: Increases to $120$ copies per $10^{6}$ PBMCs (week $54$), then $70$ to $90$.\n    -   Symptoms: Increase to $5$, then $1$ to $2$.\n    -   CRP: Rises to $18$ mg/L, then $8$ to $10$ mg/L.\n\n-   **Question**: Infer the subtype of infection state in Phase II, Phase III, and Phase IV.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientifically Grounded**: The problem describes a classic natural history of a betaherpesvirus infection (e.g., Cytomegalovirus, CMV) in an immunocompetent host, followed by reactivation due to immunosuppression. The markers used—viral DNA in plasma (viremia), intracellular lytic transcripts (IE mRNA), intracellular viral genome load (cell-associated DNA), symptoms, and a systemic inflammatory marker (CRP)—are standard and appropriate for monitoring such infections. The quantitative values and their dynamics across the phases are biologically plausible. The trigger for reactivation, prednisone (a corticosteroid), is a well-known risk factor for herpesvirus reactivation. The problem is scientifically sound.\n2.  **Well-Posed**: The problem provides a detailed, quantitative dataset and asks for a classification of infection states based on established microbiological definitions. The data are sufficient to distinguish between latent and chronic infection states. The question is clear and a unique, best-fit answer can be derived.\n3.  **Objective**: The problem is built upon objective, quantitative data and avoids subjective or ambiguous language.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. It is a well-constructed, scientifically grounded problem that can be solved by applying first principles of virology. Therefore, I will proceed with the solution derivation.\n\n**Solution Derivation**\n\nThe task requires classifying the infection states in Phases II, III, and IV. This must be done from first principles of microbiology. The key definitions are:\n\n-   **Persistent Infection**: An umbrella term for infections that are not cleared after the acute phase. The pathogen remains in the host for long periods, often for life. It includes both chronic and latent infections.\n-   **Chronic Infection**: A type of persistent infection characterized by the *continuous production of infectious virions*. This requires active, ongoing viral gene expression and replication. It is typically associated with detectable virus in body fluids (e.g., plasma), detectable lytic gene transcripts, and may be accompanied by persistent low-level symptoms and inflammation.\n-   **Latent Infection**: A type of persistent infection where the viral genome is maintained in host cells, but there is *no production of infectious virions*. Productive-cycle gene expression (e.g., immediate-early, early, late genes) is silenced. The viral genome is detectable in host cells, but markers of replication (virions in plasma, lytic transcripts) are absent or below the limits of detection. The infection is clinically quiescent. Reactivation from latency can occur, leading to a productive infection.\n\nNow, we apply these principles to the data for each phase.\n\n**Analysis of Phase II (weeks $7$ to $28$)**\n\n-   **Virologic/Molecular Data**: Plasma virion DNA is sustained at $200$ to $600$ copies/mL, which is well above the qPCR LOD of $50$ copies/mL. This indicates continuous production and shedding of virus particles into the bloodstream. IE mRNA is also sustained at $100$ to $300$ transcripts per $10^{6}$ PBMCs, far exceeding the RT-qPCR LOD of $10$. This signals ongoing, active viral gene expression initiating the lytic cycle.\n-   **Clinical/Inflammatory Data**: Symptom scores of $1$ to $2$ and elevated CRP levels ($6$ to $10$ mg/L) indicate persistent, low-grade disease activity and systemic inflammation.\n-   **Conclusion**: The combination of continuous virion production, active lytic gene transcription, and persistent low-level clinical and inflammatory signs is the definitive signature of a **chronic infection**.\n\n**Analysis of Phase III (weeks $29$ to $52$)**\n\n-   **Virologic/Molecular Data**: Plasma virion DNA is consistently $<50$ copies/mL (undetectable). IE mRNA is $<10$ transcripts per $10^{6}$ PBMCs (undetectable). This demonstrates a cessation of detectable virion production and a silencing of lytic gene expression. However, cell-associated viral DNA persists at $5$ to $20$ copies per $10^{6}$ PBMCs, which is above the LOD of $1$. This confirms the viral genome is still present within host cells.\n-   **Clinical/Inflammatory Data**: Symptom score is $0$, and CRP is at baseline ($2$ to $3$ mg/L), indicating a complete absence of disease activity.\n-   **Conclusion**: The persistence of the viral genome in the absence of detectable virus production, lytic gene expression, symptoms, or inflammation is the textbook definition of a **latent infection**. The virus is immunologically controlled and transcriptionally silent.\n\n**Analysis of Phase IV (weeks $53$ to $60$)**\n\n-   **Trigger**: The administration of prednisone, an immunosuppressant, at week $52$ breaks the state of latency.\n-   **Virologic/Molecular Data**: The virus reactivates. Plasma virion DNA rebounds sharply to $1.5 \\times 10^{4}$ copies/mL and then settles into a new plateau of $150$ to $300$ copies/mL. This level is sustained and above the LOD, indicating renewed and continuous virus production. IE mRNA expression also surges and then stabilizes at a detectable level ($200$ to $300$ transcripts), indicating a return to active lytic replication.\n-   **Clinical/Inflammatory Data**: Symptoms recur (score $5$, then $1$ to $2$), and CRP rises ($18$ mg/L, then $8$ to $10$ mg/L), signaling a return of pathology and inflammation. The state from week $55$ onwards is remarkably similar to Phase II.\n-   **Conclusion**: Phase IV begins with reactivation from latency, which then establishes a new steady state. This state, characterized by sustained virion production, active gene expression, and low-level symptoms/inflammation, is a **chronic infection**.\n\n**Summary of Classifications**:\n-   Phase II: Chronic\n-   Phase III: Latent\n-   Phase IV: Chronic\n\n**Option-by-Option Analysis**\n\nA. Phase II = chronic; Phase III = latent; Phase IV = chronic, because Phase II and IV demonstrate sustained detection of virions and immediate-early transcripts above assay LOD alongside ongoing, albeit mild, clinical and inflammatory activity, whereas Phase III shows genome persistence without detectable productive replication or symptoms.\n-   The classification of Phase II as chronic, Phase III as latent, and Phase IV as chronic perfectly matches the derivation from first principles.\n-   The justification is scientifically precise and correct. It correctly identifies the key evidence for chronicity (detectable virions and IE mRNA) and latency (genome persistence without markers of productive replication).\n-   Verdict: **Correct**.\n\nB. Phase II = persistent; Phase III = latent; Phase IV = persistent, because any infection lasting beyond the acute phase (after week $6$) is persistent regardless of replication markers, and latency is identified solely by absence of symptoms.\n-   The classification is imprecise. \"Persistent\" is a general category, not the specific subtype. The problem asks for the subtype.\n-   The justification is flawed. First, it equates latency with the mere \"absence of symptoms,\" which is incorrect; asymptomatic chronic infections exist. The defining feature of latency is the absence of productive viral replication. Second, while it is true that all phases after the acute one are \"persistent,\" this term lacks the necessary specificity to differentiate between chronic and latent states.\n-   Verdict: **Incorrect**.\n\nC. Phase II = latent; Phase III = chronic; Phase IV = chronic, because low symptom scores define latency, and recurrence of symptoms defines chronicity even if virions are undetectable.\n-   The classification is incorrect, reversing the states of Phase II and Phase III.\n-   The justification is fundamentally flawed. Low symptom scores do not define latency; Phase II has low symptoms but shows clear evidence of active replication. Chronicity is defined by persistent virus production, not just symptoms. Saying chronicity can exist \"even if virions are undetectable\" contradicts the core definition.\n-   Verdict: **Incorrect**.\n\nD. Phase II = chronic; Phase III = persistent; Phase IV = latent, because detection of any viral genome implies persistence, and following immunosuppression, the virus reenters latency after a transient spike in viremia that does not alter its latent state.\n-   The classification is incorrect for Phase III and IV. Calling Phase III \"persistent\" is imprecise. Calling Phase IV \"latent\" is factually wrong; it is a phase of active replication.\n-   The justification is illogical. It incorrectly describes Phase IV as a return to latency. The data clearly show that after the reactivation spike, a new, sustained state of chronic virus production is established, which is the opposite of latency.\n-   Verdict: **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "2519729"}, {"introduction": "Persistent infections often rely on the existence of phenotypically distinct subpopulations, such as bacterial persister cells that exhibit reduced growth and metabolic activity. This exercise moves from observation to mechanism, guiding you through the derivation of a foundational mathematical model for this form of population heterogeneity. By setting up and solving the dynamics of growth and stochastic switching between normal and persister states, you will determine the steady-state fraction of persisters, $f_{\\infty}$, revealing the elegant logic that allows a clonal population to hedge against future stresses [@problem_id:2519692].", "problem": "Consider a clonally expanding bacterial population composed of two phenotypic states: a normal, fast-growing state and a persister, slow-growing state. In a nutrient-replete environment (no external stressors), each normal cell divides with constant per-capita rate $r_{N}$ and each persister cell divides with constant per-capita rate $r_{P}$, where $r_{N} \\ge r_{P} \\ge 0$. Cells switch stochastically between states: normal to persister at rate $\\alpha$ and persister to normal at rate $\\beta$, with $\\alpha > 0$ and $\\beta > 0$. Assume mass-action kinetics for growth and switching and a well-mixed population.\n\nLet $N(t)$ and $P(t)$ denote the numbers of normal and persister cells at time $t$, and let the total population be $T(t) = N(t) + P(t)$. In exponential growth under these conditions, the population composition converges to a fixed fraction of persisters, $f_{\\infty} = \\lim_{t \\to \\infty} \\frac{P(t)}{T(t)}$, determined solely by the rates $\\alpha$, $\\beta$, $r_{N}$, and $r_{P}$.\n\nUsing only fundamental definitions of exponential growth in linear time-invariant systems and mass-action transition rates, derive an explicit closed-form expression for the steady-state persister fraction $f_{\\infty}$ in terms of $\\alpha$, $\\beta$, $r_{N}$, and $r_{P}$. Express your final answer as a single analytic expression. No numerical evaluation or rounding is required, and no units should be included in the final expression.", "solution": "The problem as stated is scientifically grounded, well-posed, objective, and self-contained. It describes a standard and fundamental model of bacterial population dynamics, specifically addressing phenotypic persistence. The parameters and assumptions are clearly defined, and the objective is to derive a specific quantity using first principles. The problem is valid for solution.\n\nLet $N(t)$ and $P(t)$ be the populations of normal and persister cells, respectively. Based on the principles of mass-action kinetics, the dynamics of the system are described by a set of coupled linear ordinary differential equations:\n$$\n\\frac{dN}{dt} = r_{N} N - \\alpha N + \\beta P\n$$\n$$\n\\frac{dP}{dt} = r_{P} P + \\alpha N - \\beta P\n$$\nThis system can be written in matrix form:\n$$\n\\frac{d}{dt} \\begin{pmatrix} N(t) \\\\ P(t) \\end{pmatrix} = \\begin{pmatrix} r_N - \\alpha & \\beta \\\\ \\alpha & r_P - \\beta \\end{pmatrix} \\begin{pmatrix} N(t) \\\\ P(t) \\end{pmatrix}\n$$\nThe problem states that for large $t$, the population grows exponentially and the composition converges to a fixed fraction of persisters, $f_{\\infty}$. This implies that the system evolves towards a state of balanced exponential growth, where both subpopulations grow at the same rate, let this rate be $\\lambda$. This rate $\\lambda$ is the dominant (largest) eigenvalue of the system matrix. In this steady-state growth phase, the fractions of normal and persister cells are constant. Let $f(t) = P(t)/T(t)$ be the fraction of persisters, where $T(t)=N(t)+P(t)$. In the long-term limit, $f(t) \\to f_{\\infty}$.\n\nIn this regime, the population sizes are given by $N(t) = (1-f_{\\infty})T(t)$ and $P(t) = f_{\\infty}T(t)$, where $\\frac{dT}{dt} = \\lambda T$. Taking the time derivative of $N(t)$ and $P(t)$, we find:\n$$\n\\frac{dN}{dt} = (1-f_{\\infty}) \\frac{dT}{dt} = \\lambda (1-f_{\\infty}) T(t)\n$$\n$$\n\\frac{dP}{dt} = f_{\\infty} \\frac{dT}{dt} = \\lambda f_{\\infty} T(t)\n$$\nSubstituting these expressions and the fractional population sizes back into the original differential equations, and dividing by the total population $T(t)$ (which is non-zero), we obtain a system of algebraic equations for $f_{\\infty}$ and $\\lambda$:\n$$\n\\lambda (1-f_{\\infty}) = (r_N - \\alpha)(1-f_{\\infty}) + \\beta f_{\\infty}\n$$\n$$\n\\lambda f_{\\infty} = \\alpha (1-f_{\\infty}) + (r_P - \\beta)f_{\\infty}\n$$\nThese two equations must be solved for $f_{\\infty}$. We can eliminate the unknown growth rate $\\lambda$. From the second equation, we can express a term containing $\\lambda$:\n$$\n\\lambda f_{\\infty} + \\beta f_{\\infty} - r_P f_{\\infty} = \\alpha(1-f_{\\infty})\n$$\n$$\n(\\lambda + \\beta - r_P) f_{\\infty} = \\alpha(1-f_{\\infty})\n$$\nIf we rearrange the first equation:\n$$\n\\lambda (1-f_{\\infty}) - (r_N - \\alpha)(1-f_{\\infty}) = \\beta f_{\\infty}\n$$\n$$\n(\\lambda - r_N + \\alpha)(1-f_{\\infty}) = \\beta f_{\\infty}\n$$\nFrom these two rearranged equations, we can isolate the terms in parentheses and set them equal through $\\beta f_{\\infty} / (1-f_{\\infty})$ (assuming $f_\\infty \\neq 1$) and $\\alpha(1-f_{\\infty})/f_\\infty$. A more direct path is to solve each for $\\lambda$:\nFrom the first equation: $\\lambda = r_N - \\alpha + \\beta \\frac{f_{\\infty}}{1-f_{\\infty}}$.\nFrom the second equation: $\\lambda = \\frac{\\alpha(1-f_{\\infty})}{f_{\\infty}} + r_P - \\beta$.\n\nEquating these two expressions for $\\lambda$:\n$$\nr_N - \\alpha + \\frac{\\beta f_{\\infty}}{1-f_{\\infty}} = \\frac{\\alpha (1-f_{\\infty})}{f_{\\infty}} + r_P - \\beta\n$$\n$$\n(r_N - r_P) + (\\alpha + \\beta) = \\frac{\\alpha (1-f_{\\infty})}{f_{\\infty}} - \\frac{\\beta f_{\\infty}}{1-f_{\\infty}}\n$$\nLet $\\Delta r = r_N - r_P$. To eliminate the fractions, multiply the entire equation by $f_{\\infty}(1-f_{\\infty})$:\n$$\n(\\Delta r + \\alpha + \\beta)f_{\\infty}(1-f_{\\infty}) = \\alpha(1-f_{\\infty})^2 - \\beta f_{\\infty}^2\n$$\n$$\n(\\Delta r + \\alpha + \\beta)(f_{\\infty} - f_{\\infty}^2) = \\alpha(1 - 2f_{\\infty} + f_{\\infty}^2) - \\beta f_{\\infty}^2\n$$\nExpanding and collecting terms based on powers of $f_{\\infty}$:\n$$\nf_{\\infty}^2: -(\\Delta r + \\alpha + \\beta) = \\alpha - \\beta \\implies -\\Delta r - \\alpha - \\beta = \\alpha - \\beta \\implies -\\Delta r = 2\\alpha \\quad (\\text{coefficients of } f_{\\infty}^2)\n$$\n$$\nf_{\\infty}: \\Delta r + \\alpha + \\beta = -2\\alpha \\quad (\\text{coefficients of } f_{\\infty})\n$$\n$$\n\\text{constant}: 0 = \\alpha \\quad (\\text{constant terms})\n$$\nThis path has an algebraic error. A less error-prone path is as follows. We begin again from the two algebraic equations:\n$1) \\quad (\\lambda - (r_N - \\alpha)) (1-f_\\infty) = \\beta f_\\infty$\n$2) \\quad (\\lambda - (r_P - \\beta)) f_\\infty = \\alpha (1-f_\\infty)$\nDividing equation $1$ by equation $2$:\n$$\n\\frac{(\\lambda - r_N + \\alpha)}{(\\lambda - r_P + \\beta)} \\frac{1-f_\\infty}{f_\\infty} = \\frac{\\beta f_\\infty}{\\alpha (1-f_\\infty)}\n$$\n$$\n(\\lambda - r_N + \\alpha) \\alpha (1-f_\\infty)^2 = (\\lambda - r_P + \\beta) \\beta f_\\infty^2\n$$\nThis path re-introduces $\\lambda$. The simplest approach leads to the quadratic equation. Let us return to it systematically.\n$$\n\\lambda - r_N + \\alpha = \\frac{\\beta f_{\\infty}}{1-f_{\\infty}} \\implies \\lambda = r_N - \\alpha + \\frac{\\beta f_{\\infty}}{1-f_{\\infty}}\n$$\nSubstitute this $\\lambda$ into the second equation $\\lambda f_{\\infty} = \\alpha (1-f_{\\infty}) + (r_P - \\beta)f_{\\infty}$:\n$$\n\\left( r_N - \\alpha + \\frac{\\beta f_{\\infty}}{1-f_{\\infty}} \\right) f_{\\infty} = \\alpha (1-f_{\\infty}) + (r_P - \\beta)f_{\\infty}\n$$\nDivide by $f_{\\infty}$ (assuming $f_{\\infty} \\neq 0$ since $\\alpha>0$):\n$$\nr_N - \\alpha + \\frac{\\beta f_{\\infty}}{1-f_{\\infty}} = \\frac{\\alpha(1-f_{\\infty})}{f_{\\infty}} + r_P - \\beta\n$$\n$$\n(r_N - r_P) + (\\alpha + \\beta) = \\frac{\\alpha}{f_{\\infty}} - \\alpha - \\frac{\\beta f_{\\infty}}{1-f_{\\infty}}\n$$\nThis is also complicated. The most robust derivation for the quadratic equation is as follows. Define $\\Delta r = r_N - r_P$.\nFrom the algebraic system:\n$1) \\lambda = (r_N - \\alpha) + \\beta \\frac{f_\\infty}{1-f_\\infty}$\n$2) \\lambda = \\alpha \\frac{1-f_\\infty}{f_\\infty} + (r_P - \\beta)$\nEquating the two expressions for $\\lambda$:\n$r_N - \\alpha + \\beta \\frac{f_\\infty}{1-f_\\infty} = r_P - \\beta + \\alpha \\frac{1-f_\\infty}{f_\\infty}$\n$r_N - r_P + \\alpha + \\beta = \\alpha \\frac{1-f_\\infty}{f_\\infty} - \\beta \\frac{f_\\infty}{1-f_\\infty} = \\frac{\\alpha(1-f_\\infty)^2 - \\beta f_\\infty^2}{f_\\infty(1-f_\\infty)}$\n$(\\Delta r + \\alpha + \\beta)(f_\\infty - f_\\infty^2) = \\alpha(1-2f_\\infty+f_\\infty^2) - \\beta f_\\infty^2$\n$(\\Delta r + \\alpha + \\beta)f_\\infty - (\\Delta r + \\alpha + \\beta)f_\\infty^2 = \\alpha - 2\\alpha f_\\infty + (\\alpha-\\beta)f_\\infty^2$\nCollecting all terms to one side:\n$$\n0 = [(\\alpha-\\beta) + (\\Delta r + \\alpha + \\beta)] f_\\infty^2 + [-2\\alpha - (\\Delta r + \\alpha + \\beta)] f_\\infty + \\alpha\n$$\n$$\n0 = (\\Delta r + 2\\alpha) f_\\infty^2 - (\\Delta r + 3\\alpha + \\beta) f_\\infty + \\alpha\n$$\nThere is an algebra mistake. Let us restart from the clean system:\n$\\lambda(1-p) = (r_N-\\alpha)(1-p) + \\beta p$\n$\\lambda p = \\alpha(1-p) + (r_P-\\beta)p$\nwhere $p=f_\\infty$.\n$p(\\lambda + \\alpha - r_P + \\beta) = \\alpha \\implies p = \\frac{\\alpha}{\\lambda - r_P + \\alpha + \\beta}$\n$(1-p)(\\lambda - r_N + \\alpha) = \\beta p \\implies \\lambda - r_N + \\alpha = \\frac{\\beta p}{1-p}$\nFrom the second relation, $\\lambda = r_N - \\alpha + \\frac{\\beta p}{1-p}$.\nSubstitute into the first one:\n$p = \\frac{\\alpha}{(r_N - \\alpha + \\frac{\\beta p}{1-p}) - r_P + \\alpha + \\beta} = \\frac{\\alpha}{(r_N - r_P) + \\beta + \\frac{\\beta p}{1-p}}$\n$p \\left( (r_N-r_P) + \\beta + \\frac{\\beta p}{1-p} \\right) = \\alpha$\n$p(\\Delta r + \\beta) + \\frac{\\beta p^2}{1-p} = \\alpha$\nMultiply by $(1-p)$:\n$p(1-p)(\\Delta r + \\beta) + \\beta p^2 = \\alpha(1-p)$\n$(\\Delta r + \\beta)(p - p^2) + \\beta p^2 = \\alpha - \\alpha p$\n$(\\Delta r + \\beta)p - (\\Delta r + \\beta)p^2 + \\beta p^2 = \\alpha - \\alpha p$\n$-\\Delta r \\cdot p^2 + (\\Delta r + \\beta + \\alpha)p - \\alpha = 0$\nMultiplying by $-1$ gives the quadratic equation for $p = f_{\\infty}$:\n$$\n(r_N - r_P) f_{\\infty}^2 - (r_N - r_P + \\alpha + \\beta) f_{\\infty} + \\alpha = 0\n$$\nThis is a quadratic equation of the form $ax^2+bx+c=0$ with $a=r_N-r_P$, $b=-(r_N-r_P+\\alpha+\\beta)$, $c=\\alpha$.\nThe solutions are given by the quadratic formula $x = \\frac{-b \\pm \\sqrt{b^2-4ac}}{2a}$.\nThere are two mathematical solutions. We must select the one that is physically meaningful (i.e., $0 \\le f_{\\infty} \\le 1$). A more robust form of the solution for the numerically smaller root is $x = \\frac{2c}{-b + \\sqrt{b^2-4ac}}$. For our problem, the physical root corresponds to the smaller of the two solutions. Let us use this form.\n$$\nf_{\\infty} = \\frac{2\\alpha}{(r_N - r_P + \\alpha + \\beta) + \\sqrt{(r_N - r_P + \\alpha + \\beta)^2 - 4\\alpha(r_N - r_P)}}\n$$\nThis expression is the correct stable fixed point. The \"+\" sign is chosen in the denominator to select the smaller root which corresponds to the stable steady state fraction. This form is also well-behaved in the limit $r_N \\to r_P$, where it correctly simplifies to $f_{\\infty} = \\frac{\\alpha}{\\alpha+\\beta}$.\n\nThe term under the square root can be expanded and refactored as:\n$(r_N-r_P+\\alpha+\\beta)^2 - 4\\alpha(r_N-r_P) = (r_N-r_P)^2 + 2(r_N-r_P)(\\alpha+\\beta) + (\\alpha+\\beta)^2 - 4\\alpha(r_N-r_P)$\n$= (r_N-r_P)^2 + 2(r_N-r_P)(\\beta-\\alpha) + (\\alpha+\\beta)^2$\n$= (r_N-r_P)^2 - 2(r_N-r_P)(\\alpha-\\beta) + (\\alpha-\\beta)^2 + 4\\alpha\\beta = (r_N-r_P - (\\alpha-\\beta))^2 + 4\\alpha\\beta$\n$= (r_N-r_P - \\alpha + \\beta)^2 + 4\\alpha\\beta$.\nWhile this form is more compact, we will use the un-rearranged version for the final expression as it follows directly from the quadratic formula.\nThe final closed-form expression for the steady-state persister fraction is therefore determined.", "answer": "$$\n\\boxed{\\frac{2\\alpha}{(r_N - r_P + \\alpha + \\beta) + \\sqrt{(r_N - r_P + \\alpha + \\beta)^2 - 4\\alpha(r_N - r_P)}}}\n$$", "id": "2519692"}, {"introduction": "A key challenge in managing latent infections like HIV is quantifying the hidden reservoir and predicting its clinical impact. This problem provides hands-on practice in bridging the gap from a laboratory assay to a patient-level prognosis. You will use data from a Quantitative Viral Outgrowth Assay (QVOA) to estimate the total size of the replication-competent HIV reservoir and then apply a stochastic activation model to calculate the expected time to viral rebound after therapy cessation, a critical parameter in cure research [@problem_id:2519670].", "problem": "A person living with Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy (ART) has been evaluated with a Quantitative Viral Outgrowth Assay (QVOA). The QVOA reports a frequency of replication-competent latent infection of $0.80$ infectious units per million resting memory $\\mathrm{CD4}^{+}$ T cells (IUPM). An independent immunological study estimates that the total body pool of resting memory $\\mathrm{CD4}^{+}$ T cells for this individual is $4.0 \\times 10^{10}$ cells. After ART cessation at time $t=0$, assume the following:\n- Each latently infected cell independently undergoes stochastic activation with a constant hazard (per-cell activation rate) of $a = 1.0 \\times 10^{-5} \\ \\mathrm{day}^{-1}$.\n- Conditional on an activation event occurring, the probability that this event seeds a lineage that avoids stochastic extinction and grows to systemic viremia is $p_{s} = 0.25$. Assume independence across activation events and cells.\n- Before $t=0$, replication is fully suppressed by ART so that no activation events contribute to systemic viremia.\n\nUsing only the definitions of IUPM and resting memory $\\mathrm{CD4}^{+}$ T cell pool size, and standard properties of independent Poisson activation processes and rare-event thinning, do the following:\n1. From first principles, compute the expected number of replication-competent latently infected cells in the body at $t=0$ (the size of the replication-competent reservoir).\n2. Model activation events across all reservoir cells as independent Poisson processes and derive the expected waiting time to the first successful activation that leads to systemic rebound after ART cessation.\n\nExpress the reservoir size as a number of cells and the expected time to rebound in days. Round each to three significant figures. Report your final result as a row vector $\\begin{pmatrix}\\text{reservoir size} & \\text{expected time to rebound (days)}\\end{pmatrix}$.", "solution": "The goal is to translate the assay-based frequency of replication-competent latent infection into an absolute count of such cells, and then to use a stochastic activation framework to compute the expected time to the first successful activation event after Antiretroviral Therapy (ART) cessation.\n\nFirst, use the definition of the Quantitative Viral Outgrowth Assay (QVOA). The QVOA reports $0.80$ infectious units per million cells, meaning that, on average, there are $0.80$ replication-competent latently infected cells per $10^{6}$ resting memory $\\mathrm{CD4}^{+}$ T cells. Let $f$ denote the QVOA frequency in infectious units per million cells and let $T_{\\mathrm{mem}}$ denote the total number of resting memory $\\mathrm{CD4}^{+}$ T cells. The expected number of replication-competent latently infected cells, $N$, is obtained by scaling the per-million frequency to the full pool:\n$$\nN \\;=\\; f \\times \\frac{T_{\\mathrm{mem}}}{10^{6}}.\n$$\nHere, $f = 0.80$ and $T_{\\mathrm{mem}} = 4.0 \\times 10^{10}$. Substituting,\n$$\nN \\;=\\; 0.80 \\times \\frac{4.0 \\times 10^{10}}{10^{6}}\n\\;=\\; 0.80 \\times 4.0 \\times 10^{4}\n\\;=\\; 3.2 \\times 10^{4}.\n$$\nThus, the expected replication-competent reservoir size is $3.2 \\times 10^{4}$ cells.\n\nSecond, model time to rebound. After ART cessation at time $t=0$, assume each of the $N$ latently infected cells independently activates according to a Poisson process with per-cell hazard (rate) $a = 1.0 \\times 10^{-5} \\ \\mathrm{day}^{-1}$. The superposition of $N$ independent Poisson processes with rate $a$ is a Poisson process with rate $N a$. However, not every activation event will establish a lineage that avoids stochastic extinction and progresses to systemic viremia; let the per-event success probability be $p_{s} = 0.25$. Thinning a Poisson process by independently retaining each event with probability $p_{s}$ yields another Poisson process with rate\n$$\n\\lambda \\;=\\; N \\, a \\, p_{s}.\n$$\nThe time to the first successful activation event is the waiting time to the first event in a Poisson process of rate $\\lambda$. Let $T$ denote this waiting time. For a Poisson process with rate $\\lambda$, the survival function for the time to the first event is $S(t) = \\Pr(T>t) = \\exp(-\\lambda t)$, which implies an exponential distribution with mean\n$$\n\\mathbb{E}[T] \\;=\\; \\int_{0}^{\\infty} S(t)\\, dt \\;=\\; \\int_{0}^{\\infty} \\exp(-\\lambda t)\\, dt \\;=\\; \\frac{1}{\\lambda}.\n$$\nTherefore,\n$$\n\\mathbb{E}[T] \\;=\\; \\frac{1}{N a p_{s}}.\n$$\nNow substitute the values. We have $N = 3.2 \\times 10^{4}$, $a = 1.0 \\times 10^{-5} \\ \\mathrm{day}^{-1}$, and $p_{s} = 0.25$. Compute the effective rate:\n$$\n\\lambda \\;=\\; \\left(3.2 \\times 10^{4}\\right)\\left(1.0 \\times 10^{-5}\\right)\\left(0.25\\right)\n= \\left(3.2 \\times 10^{4}\\right)\\left(2.5 \\times 10^{-6}\\right)\n= 8.0 \\times 10^{-2}.\n$$\nHence,\n$$\n\\mathbb{E}[T] \\;=\\; \\frac{1}{8.0 \\times 10^{-2}} \\;=\\; 12.5 \\ \\text{days}.\n$$\nFinally, apply the rounding instruction to three significant figures. The reservoir size $N = 3.2 \\times 10^{4}$ becomes $3.20 \\times 10^{4}$ when expressed to three significant figures, and the expected time to rebound remains $12.5$ days at three significant figures.\n\nThus, the requested row vector is $\\begin{pmatrix}3.20 \\times 10^{4} & 12.5\\end{pmatrix}$.", "answer": "$$\\boxed{\\begin{pmatrix}3.20 \\times 10^{4} & 12.5\\end{pmatrix}}$$", "id": "2519670"}]}